Question for written answer E-003566/2021
to the Commission
Rule 138
Paul Tang (S&D), Aurore Lalucq (S&D)

Subject: Tax avoidance by Moderna

On 13 July 2021, the Centre for Research on Multinational Corporations (SOMO) published research
on tax avoidance by the vaccine manufacturer Moderna. The contract between the Commission and
Moderna indicates that the latter diverts payments from the USD 10 billion dollar contract to tax
havens. Its subsidiary in Basel is a typical letterbox company with no substantial economic activity,
likely set up for fiscal reasons. Similarly, Moderna’s office in Delaware, where its intellectual property
rights are held, does not have to pay any taxes on royalties or publish an annual report. Tax
avoidance is always unacceptable, but is even more deplorable in this case considering that the
Moderna vaccine was developed and then purchased using public funds.

1. Is the Commission aware of the aggressive tax avoidance schemes that Moderna uses?

2. If the Commission still recommends not granting financial support to companies with links to tax
   havens, as it did last year, should the same not apply to companies that have a contract with the
   Commission itself?

3. Has it considered demanding that vaccine producers pay their fair share of taxes and improve
   transparency if they sign contracts with the Commission, and if not, will it do so in the future?